Pfizer's Potential Blockbuster Heart Drug Boosted by Study
- Alnylam shares surge as Pfizer won’t pursue competing usage
- Tafamidis treats fatal disease doctors say is underdiagnosed
This article is for subscribers only.
Pfizer Inc.’s pipeline may finally be delivering.
A new study shows that patients with a rare condition that can lead to heart failure lowered their risk of dying by 30 percent after being treated with Pfizer’s tafamidis. The finding could give the biggest U.S. drugmaker another potential blockbuster medicine and challenge a biotech startup marketing its own groundbreaking treatment for the same disease.